The mix-up prompted federal regulators to delay authorization of the plant’s production lines. : BALTIMORE — The Emergent BioSolutions manufacturing plant in East Baltimore that has been making coronavirus vaccine for months has not yet received emergency use authorization from the federal government, a spokesperson confirmed Wednesday. A report Wednesday from The New York Times attributed the delay to a mix-up of two vaccines’ ingredients several weeks ago, which ruined about 15 million doses of Johnson & Johnson’s vaccine and forced regulators to delay authorization of the plant’s production lines.